BioCryst Announces Late Breaker Presentation of OPuS-1

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
BioCryst Announces Late Breaker Presentation of OPuS-1 Phase 2 Trial Results at the 23rd EADV Congress

RESEARCH TRIANGLE PARK, N.C., Oct. 7, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. , (Nasdaq: BCRX ) today announced that results from its successful OPuS-1 ( O ral P rophylaxi S-1 ) proof of concept Phase 2a clinical trial of orally-administered BCX4161 in patients with hereditary angioedema (HAE) will be presented as a late-breaker oral presentation at the 23 rd EADV Congress taking place in Amsterdam October 8-12, 2014.

The presentation titled "BCX4161, an Oral Kallikrein Inhibitor, is effective and safe in the Prophylaxis of Acute Attacks in Patients with Hereditary Angioedema: Results of the Phase 2 Trial OPuS-1," will be presented by Marcus Maurer MD , Professor of Dermatology and Allergy, Charité-Universitäsmedizin, Berlin and the principal investigator for OPuS-1. The presentation will take place during the "Late Breaking News in Dermatology" session on Saturday, October 11 at 1:00 PM Central European Time.

OPuS-1 evaluated 400 mg of BCX4161 administered three times a day for 28 days in HAE patients with a high attack frequency (≥ 1 per week), in a randomized, double-blind, placebo-controlled, two-period cross-over design. The primary goals for the trial were to estimate the degree of efficacy of BCX4161 in reducing the frequency of angioedema attacks, and to evaluate the safety and tolerability of 28 days of BCX4161 treatment. The trial met the primary efficacy endpoint and all other objectives established for the trial.

BioCryst expects to initiate its OPuS-2 trial to evaluate the efficacy and safety of BCX4161 treatment for 12 weeks in patients with HAE before the end of 2014.

About BCX4161

Discovered by BioCryst, BCX4161 is a novel, selective inhibitor of plasma kallikrein in development for prevention of attacks in patients with hereditary angioedema (HAE). By inhibiting plasma kallikrein, BCX4161 suppresses bradykinin production. Bradykinin is the mediator of acute swelling attacks in HAE patients.

About Hereditary Angioedema

HAE is a rare, severely debilitating and potentially fatal genetic condition that occurs in about 1 in 10,000 to 1 in 50,000 people. HAE symptoms include recurrent episodes of edema in various locations, including the hands, feet, face, genitalia and airway. In addition, patients often have bouts of excruciating abdominal pain, nausea and vomiting that are caused by swelling in the intestinal wall. Airway swelling is particularly dangerous and can lead to death by asphyxiation. Further information regarding HAE can be found at www.haea.org .

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in infectious and rare diseases, with the goal of addressing unmet medical needs of patients and physicians. BioCryst's core development programs include BCX4161 and two next generation oral inhibitors of plasma kallikrein for hereditary angioedema; peramivir , a viral neuraminidase inhibitor for the treatment of influenza; and BCX4430 , a broad spectrum antiviral for hemorrhagic fevers. For more information, please visit the Company's website at www.BioCryst.com .

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause BioCryst's actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: that the FDA or similar regulatory agency may refuse to approve subsequent HAE studies, or delay approval of clinical studies which may result in a delay of planned clinical studies and increase development costs of a product candidate; that the FDA may withhold market approval for product candidates; that ongoing and future preclinical and clinical development of HAE second generation candidates may not have positive results; that the Company or its licensees may not be able to continue future development of current and future development programs; that such development programs may never result in future product, license or royalty payments being received; that the Company may not be able to retain its current pharmaceutical and biotechnology partners for further development of its product candidates or may not reach favorable agreements with potential pharmaceutical and biotechnology partners for further development of product candidates. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and current reports on Form 8-K, all of which identify important factors that could cause the actual results to differ materially from those contained in BioCryst's projections and forward-looking statements.

BCRXW

Robert Bennett, BioCryst Pharmaceuticals, +1-919-859-7910

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AvidXchange Acquisition Faces Fairness Investigation

Updated Category News Views 269

Unpacking the AvidXchange Turmoil Staring at the ticker tape feels like watching a drama unfold, and today it's all about AvidXchange Holdings, Inc. (NASDAQ: AVDX). Levi & Korsinsky, LLP has launched an investigation into the fairness of its acquisition, and let me tell you, when the suits start poking around, it means someone smells a rat. The deal in question? A buyout...

Continue Reading
NaLA Pushes for Stronger Lifeline Fraud Measures

Updated Category News Views 89

Here's the thing about the Lifeline program: it's meant to be a lifeline, not a loophole for the crafty and unscrupulous. The National Lifeline Association (NaLA) is slamming the table, demanding that the Senate Commerce Committee put some real muscle into preventing fraud. Why the Urgency on Lifeline Fraud? NaLA’s got its sights on a more robust defensive line against...

Continue Reading
Cardio Partners Hits a Million Milestone with Red Cross

Updated Category News Views 121

One Million Trained, One Million Prepared Ah, a million sounds like just another number, doesn't it? But when someone's life hangs in the balance, those are a million folks ready to jump in and act. Cardio Partners has hit this mighty milestone in CPR, AED, and First Aid training, gaining a pat on the back from none other than the American Red Cross. It's a testament,...

Continue Reading
Blueprint Strengthens Team with New Capital Markets Director

Updated Category News Views 114

Blueprint Bolsters Its Ranks Hiring Caitlin Novak as Managing Director marks a pivotal step for Blueprint Healthcare Real Estate Advisors. They aren't just swapping pawns; they're making a statement, beefing up their capital markets strategy with a heavy hitter seasoned in steering around fiscal pitfalls. Novak isn’t some rookie wet behind the ears—she's clocked more...

Continue Reading
Duolingo Faces Class Action: Key Investor Steps

Updated Category News Views 162

Navigating Turbulent Times with Duolingo Holy moly, the dumpster fire that is the Duolingo (NASDAQ:DUOL) legal saga just got hotter. If you snagged yourself some shares between May 2, 2025, and February 26, 2026, you'd better sit down and grab some antacids—because the nauseating roller coaster is far from over. Robbins LLP is rounding up the troops for a class action,...

Continue Reading
DHL Leverages Robust Growth in Resilient Supply Chains

Updated Category News Views 186

Supply Chain Resilience: A Strategic Game Changer Market volatility's got its teeth in the game, and everyone in logistics knows it. DHL Supply Chain isn't just sitting back; they're riding the wave of change, snagging a 12% revenue bump in 2026. It's not your typical headline growth, either. More like the kind of growth that gets logistics gurus eyeing those contract...

Continue Reading
Grupo Supervielle's Q3 2026: Back to Growth Path

Updated Category News Views 66

Mounting Momentum in Loans and Asset Quality Grupo Supervielle, the Argentine financial player, has been tinkering with its gears to navigate the bumpy roads of 2026. In the third quarter, the company reports a gentle uptick in net loans—up 1.3% sequentially. This was particularly felt in September, with loans increasing 3.7%. Holding Their Own Against the Industry...

Continue Reading
Radiate Holdco's Q3 Results: What We Know Now

Updated Category News Views 77

Digging Into Third Quarter Highlights Radiate Holdco, LLC has just thrown its third-quarter financial hat into the ring, stirring up some interest in the world of FLFO secured notes and senior notes. The folks in Princeton, N.J., sure know how to keep things exclusive—this intel is only for those holding their Notes or in the pretty exclusive club of qualified...

Continue Reading
IP Lawyer Chris Henry Returns to Latham: A Game Changer

Updated Category News Views 202

Welcome Home, Chris Henry! Folks, here's a headline that's making waves in the IP litigation water: Chris Henry has returned to Latham & Watkins, taking his place as a heavyweight partner in their Boston office. Now, if you're not deeply entangled in the world of high-stakes intellectual property (IP) disputes, you might shrug. But for tech companies embroiled in patent...

Continue Reading
Copper Peptides Shine in New Renue Blue Cream

Updated Category News Views 171

Renue By Science's Ambitious Skincare Launch Alright, we've got a big player stepping up in the realm of skincare with a new face cream packed tightly with science-backed goodies. Renue By Science is revamping their game by anchoring their new Renue Blue Face Cream around the star of the moment: copper tripeptide-1, also known as GHK-Cu. This is more than a beauty gloss...

Continue Reading

Top 5 Most Recently Viewed Articles

CNB Community Bancorp Raises Quarterly Dividend to $0.30

Updated Category News Views 103

CNB Community Bancorp Declares Increased Cash Dividend CNB Community Bancorp, Inc. has recently made an exciting announcement regarding its financial strategy. The Board of Directors has officially declared a quarterly cash dividend of $0.30 per share for the company’s common stock. This new dividend reflects an increase of $0.01 per share compared to the previous...

Continue Reading
Exciting Primark Store Opening at Wolfchase Galleria

Updated Category News Views 410

Exciting Primark Store Opening at Wolfchase Galleria Primark, a global favorite in fashion retail, is set to make a splash in the U.S. by opening its first Tennessee store. Located at Wolfchase Galleria, this grand opening signifies a pivotal moment for the brand, as it marks their 31st U.S. location, proudly spreading across various states. With the new store covering...

Continue Reading
Continuous Gold Processing at North Bay Resources' Mill

Updated Category News Views 145

Exciting Developments at North Bay Resources North Bay Resources, Inc. (the “Company” or “North Bay”) (OTC: NBRI) is thrilled to announce the successful continuous operations of its Bishop Gold Mill. Following significant upgrades made recently, the mill has been running successfully for up to nine hours a day. This achievement has led to the processing of...

Continue Reading
Insider Stock Purchase Highlights Marriott Vacations Growth Potential

Updated Category News Views 130

Insight into Recent Stock Transactions A significant insider purchase was reported by Lizanne Galbreath, a Board Member at Marriott Vacations (NYSE: VAC), showcasing her confidence in the company’s future. This transaction involved the acquisition of 5,500 shares, valued at approximately $255,805, as submitted in a Form 4 filing to the SEC. Such transactions often...

Continue Reading
Market Reaction to Potential Fed Chair Nomination Shakes Up Trends

Updated Category News Views 161

Market Reaction to Potential Fed Chair Nomination Recent market trends show significant fluctuations as rumors circulate about President Trump’s forthcoming announcement regarding a new chairman for the Federal Reserve. The spotlight is on former Fed Governor Kevin Warsh, expected to be nominated later today, which sends ripples through the gold and dollar markets....

Continue Reading